• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Auspex Pharmaceuticals

edit

Auspex Pharmaceuticals, Inc., a deuteration company, engages in developing a pipeline of therapeutics that improves on existing drugs across various therapeutic areas. The company focuses on developing SD-254, a deuterium-substituted version of venlafaxine, for the treatment of depressive disorders. The company was founded in 2001 and is based in Vista, California.

Milestones

edit

• 
  Auspex Pharmaceuticals added R. Gary Gilmore as CFO.
  Posted 10/19/10 at 2:46am
• 
  Auspex Pharmaceuticals added Andreas Sommer as COO.
  Posted 10/19/10 at 2:46am
• 
  Auspex Pharmaceuticals received $12M in Series C funding. (10/13/10)
  Posted 10/19/10 at 2:46am via onbiovc.com

Videos

Screenshots

edit

Sources

1. Auspex Pharmaceuticals, Inc.: $12M Series C (onbiovc.com) [edit]